Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Teduglutide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 7/20 | 0.82 |
| ▸ | CCKBR | P32239 | 1/20 | 0.82 |
| ▸ | PTH1R | Q03431 | 10/20 | 0.79 |
| ▸ | ECE1 | P42892 | 1/20 | 0.76 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.76 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.71 |
| ▸ | VIPR1 | P32241 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Teduglutide SCHEMBL20898050 | 1.00 | GLP1R (0.82) | GLP1RCCKBRPTH1RECE1MUS81 | |
| SCHEMBL29376455 | 0.99 | PTH1R (0.81) | GLP1RCCKBRPTH1RECE1MUS81 | |
| Oxyntomodulin SCHEMBL29349603 | 0.94 | GLP1R (0.84) | GLP1RCCKBRPTH1RECE1MUS81 | |
| Teduglutide SCHEMBL29393085 | 0.93 | GLP1R (0.73) | GLP1RCCKBRPTH1R | |
| SCHEMBL29022672 | 0.93 | GLP1R (0.73) | GLP1RCCKBRPTH1RECE1MUS81 | |
| SCHEMBL29385782 | 0.93 | GLP1R (0.73) | GLP1RCCKBRPTH1R | |
| SCHEMBL30658300 | 0.92 | PTH1R (0.72) | GLP1RCCKBRPTH1RECE1MUS81 | |
| SCHEMBL29527049 | 0.92 | PTH1R (0.72) | GLP1RCCKBRPTH1RECE1MUS81 | |
| SCHEMBL30657454 | 0.92 | GLP1R (0.75) | GLP1RCCKBRPTH1R | |
| SCHEMBL31060658 | 0.92 | GLP1R (0.89) | GLP1RCCKBRPTH1RECE1MUS81 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 200 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388643-A1 | GLUCAGON-LIKE PEPTIDE-2 COMPOSITIONS AND METHODS OF MAKING AND USING SAME | AMUNIX PHARMACEUTICALS, INC. (US) | 2025-12-25 | — | — | US | claimed |
| US-20240415933-A1 | STABLE INJECTABLE COMPOSITIONS OF GLP-2 PEPTIDE | ORBICULAR PHARMACEUTICAL TECH PRIVATE LIMITED (IN) | 2024-12-19 | — | — | US | claimed |
| WO-2024075135-A1 | \"STABLE INJECTABLE COMPOSITIONS OF GLP-2 PEPTIDE\ | ORBICULAR PHARMACEUTICAL TECHNOLOGIES PRIVATE LIMITED (IN) | 2024-04-11 | — | — | WO | claimed |
| US-20240067695-A1 | GLUCAGON-LIKE PEPTIDE-2 COMPOSITIONS AND METHODS OF MAKING AND USING SAME | AMUNIX PHARMACEUTICALS INC (US) | 2024-02-29 | — | — | US | claimed |
| US-20230364196-A1 | METHODS FOR TREATING GRAFT-VERSUS-HOST DISEASE USING GLP-2 AGONISTS AND ANALOGUES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2023-11-16 | — | — | US | claimed |
| CN-115054683-B | Application of glucagon-like peptide-2 in preparation of drug for relieving doxorubicin cardiotoxicity | 唐颢 | 2023-06-09 | — | — | CN | claimed |
| CN-115054683-A | Application of glucagon-like peptide-2 in preparation of adriamycin cardiotoxicity relieving medicine | 唐颢 | 2022-09-16 | — | — | CN | claimed |
| US-20220280654-A1 | IMPROVED CONJUGATION LINKERS | PROLYNX LLC (US) | 2022-09-08 | — | — | US | claimed |
| WO-2022159555-A1 | METHODS FOR TREATING GRAFT-VERSUS-HOST DISEASE USING GLP-2 AGONISTS AND ANALOGUES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2022-07-28 | — | — | WO | claimed |
| CN-114286693-A | Improved coupling joint | 普罗林科斯有限责任公司 | 2022-04-05 | — | — | CN | claimed |
| EP-3946460-B1 | IMPROVED CONJUGATION LINKERS | PROLYNX LLC (US) | 2026-05-20 | — | — | EP | disclosed |
| US-12617831-B2 | Peptide targeting GIP and GLP-2 receptors for treating bone disorders | UNIVERSITE D'ANGERS (FR) | 2026-05-05 | — | — | US | disclosed |
| US-20260116943-A1 | PROCESSES FOR SYNTHESIZING GLUCAGON-LIKE-PEPTIDE 2 (GLP-2) ANALOGUES | ZEALAND PHARMA AS (DK) | 2026-04-30 | — | — | US | disclosed |
| US-20260116928-A1 | COMPOSITIONS AND PARTICLES FOR PAYLOAD DELIVERY | THORNHILL THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4120958-B1 | IMPLANTABLE CELL CHAMBER DEVICE AND USES THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2026-04-29 | — | — | EP | disclosed |
| CN-114286693-A | Improved coupling joint | 普罗林科斯有限责任公司 | 2022-04-05 | — | — | CN | disclosed |
| CN-114213524-A | Coating antigen for detecting glucagon-like peptide-2 antibody, purification method, recombinant engineering bacteria and culture method | 苏州博领干细胞再生医学有限公司 | 2022-03-22 | — | — | CN | disclosed |
| US-20220072104-A1 | MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH | 2022-03-10 | — | — | US | disclosed |
| US-20220031810-A1 | FORMULATIONS OF GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES | ZEALAND PHARMA A/S (DK) | 2022-02-03 | — | — | US | disclosed |
| US-20220033454-A1 | INTERLEUKIN-22 FUSION PROTEINS, AND THEIR PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC APPLICATIONS | ANWITA BIOSCIENCES, INC. (US) | 2022-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033454-A1 | INTERLEUKIN-22 FUSION PROTEINS, AND THEIR PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC APPLICATIONS | IL2, IL36G, ALB | GLP1R 1285/4885CCKBR 3387/4885PTH1R 1783/4885 |
| US-20220072104-A1 | MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF | SGMS1, TYMP, TK2 | GLP1R 3958/4885CCKBR 3613/4885PTH1R 500/4885 |
| US-20250388643-A1 | GLUCAGON-LIKE PEPTIDE-2 COMPOSITIONS AND METHODS OF MAKING AND USING SAME | VIP, GLP1R, GIPR | GLP1R 2/4885CCKBR 26/4885PTH1R 145/4885 |
| US-20220280654-A1 | IMPROVED CONJUGATION LINKERS | DNPEP, SPPL2B, PTMS | GLP1R 321/4885CCKBR 1023/4885PTH1R 937/4885 |
| US-20260116943-A1 | PROCESSES FOR SYNTHESIZING GLUCAGON-LIKE-PEPTIDE 2 (GLP-2) ANALOGUES | GLP1R, PTMS, GCG | GLP1R 1/4885CCKBR 144/4885PTH1R 48/4885 |
| US-20260116928-A1 | COMPOSITIONS AND PARTICLES FOR PAYLOAD DELIVERY | SLC47A2, SLC47A1, SLC39A14 | GLP1R 671/4885CCKBR 311/4885PTH1R 603/4885 |
| US-12617831-B2 | Peptide targeting GIP and GLP-2 receptors for treating bone disorders | GLP1R, GIPR, VIP | GLP1R 1/4885CCKBR 107/4885PTH1R 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.